Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Subscribe To Our Newsletter & Stay Updated